April 4, 2022

This communication is being sent to all key contacts at provider organizations administering COVID-19 vaccine—please read this message in its entirety. Please feel free to share it with others in your organization who may benefit from the update. Note that all our communications are archived on our web site.

Dear Connecticut COVID-19 Vaccine Providers,

The Centers for Disease Control and Prevention (CDC) updated the Interim Clinical Considerations for Use of COVID-19 Vaccines currently authorized or approved in the United States to reflect the recommendation of a second booster dose for specific populations. See the published language relating to second booster dose recommendations below:

- People ages 12 years and older who are *moderately or severely immunocompromised* may choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
- Adults ages 50 years and older who are not moderately or severely immunocompromised may choose to receive a *second booster dose* using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
- People ages 18–49 years who are not moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose.

Please note, the definition of up to date has not changed. Receipt of a second booster dose is not necessary to be considered up to date at this time.

In addition to the Interim Clinical Considerations, CDC has also updated the Summary Document for Interim Clinical Considerations and the schedule timeline for vaccination of persons who are moderately or severely immunocompromised.

All COVID-19 vaccine providers should make the second booster dose available for those eligible who seek it. Persons who are eligible and seeking a dose should not be turned away. Connecticut DPH continues to support patient self-identification and attestation as a sufficient basis for confirming that an individual is eligible for a second booster.

FDA VRBPAC meeting scheduled for April 6th to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants. No votes are expected.
Additional Moderna Product Presentation Approved

The Moderna Emergency Use Authorization (EUA) was recently updated to reflect the availability of a new booster dose presentation. While the dose volume differs, this presentation contains the same ingredients and is the same strain formulation as the currently available product. The new product is a 50ug dose presented as a 5-dose multi-dose vial with a dark blue cap and purple border and is 0.5 mL injection volume. This presentation is indicated for booster dose use only and is not approved or indicated for use as a primary dose in the Moderna series.

This product is not yet available for order. Additional information regarding availability will be distributed as it becomes available.

For the CT DPH Immunization Program, visit: Contact Us
For the COVID-19 webpage, visit: COVID-19 Vaccine Program

If you would like to unsubscribe from these communications, please send an email to Dph.immunizations@ct.gov with the subject line “Unsubscribe from COVID-19 Program communications”.